Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
AlvotechNASDAQ: ALVO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $46.09M fell 29.6% year over year, behind the -6.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 24.8% from the prior quarter. Over 3 fiscal years it compounded at +54.3% a year.
Context
- Cost of revenue amounted to 40.2% of revenue in FY2025, up 2.3 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.6% toward the trailing-twelve-month pace of -6.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 235.56M USD
- Year-over-year change
- +27.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 235.56M | +27.1% |
| FY2024 | 2024-12-31 | 185.31M | +15.2% |
| FY2023 | 2023-12-31 | 160.86M | +151.0% |
| FY2022 | 2022-12-31 | 64.1M | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 cost of revenue of $216.2M is the 9th highest of the 11 companies compared; the peer median is $2.12B.
- Its year-over-year change of -6.3% is the 10th highest of 11, against a peer median of +8.9%.
- Cost of revenue amounts to 38.6% of revenue for ALVO, versus a peer median of 42.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.43B | -15.9% | +18.8% | 27.3% | |
| LTM Jun 2026 | $8.23B | -1.8% | +1.5% | 47.5% | |
| LTM Jun 2026 | $3.21B | +17.0% | +8.3% | 32.3% | |
| LTM Sep 2026 | $2.84B | +0.3% | +7.6% | 46.6% | |
| LTM Jun 2026 | $2.35B | +14.7% | +7.2% | 15.1% | |
| LTM Jun 2026 | $1.89B | +6.4% | +9.8% | 60.7% | |
| LTM Mar 2026 | $379.4M | +5.6% | +13.3% | 52.7% | |
| LTM Mar 2026 | $313.15M | +11.4% | +7.6% | 39.3% | |
| LTM Mar 2026 | $216.2M | -6.3% | +54.3% | 38.6% | |
| LTM Mar 2026 | $69.57M | +28.3% | +38.8% | 25.9% | |
| LTM Mar 2026 | $39.32M | +96.0% | +75.1% | 45.2% | |
| Peer median (excluding ALVO) | $2.12B | +8.9% | +9.1% | 42.3% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.77M | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | 0 | 64.1M | 160.86M | 185.31M | 235.56M |
| Gross Profit | 36.77M | 18.93M | (69.42M) | 304.37M | 350.76M |
| Gross Margin | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| Research & Development | 191.01M | 180.62M | 210.83M | 171.31M | 184.19M |
| Selling, General & Admin | 84.13M | 186.74M | 73.04M | 61.45M | 90.95M |
| Operating Expenses | 272.23M | 365.38M | 285.44M | 234.73M | 272.56M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| EBITDA | (18.03M) | (439.8M) | (493.67M) | (32.28M) | 323.39M |
| EBITDA Margin | -49.0% | -529.7% | -539.9% | -6.6% | 55.2% |
| Operating Income | (235.46M) | (346.44M) | (354.86M) | 69.64M | 78.21M |
| Operating Margin | -640.3% | -417.3% | -388.1% | 14.2% | 13.3% |
| Interest Income | 19K | 912K | 4.82M | 4.62M | 198.49M |
| Interest Expense | 112.97M | 91.44M | 134.82M | 157.6M | 149.19M |
| Other Income / Expenses | 86.26M | (205.21M) | (296.19M) | (287.21M) | 58.14M |
| Income Before Tax | (149.2M) | (551.65M) | (651.05M) | (217.56M) | 136.35M |
| Pre-Tax Margin | -405.7% | -664.4% | -712.0% | -44.4% | 23.3% |
| Income Tax Expense | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Net Margin | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |
| EPS (Basic) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| EPS (Diluted) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| Weighted Avg Shares | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.